Related Experiment Video
Updated: May 3, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Cocaine and repolarization disorder: myocardial ischemia?
Bruce Imbert1, Anis Bouchefra, Nathalie Labrune
1Department of Addictology Sainte-Marguerite University Hospital Assistance Publique - Hôpitaux de Marseille Marseille, France bruce.imbert@ap-hm.fr Department of AddictologySainte-Marguerite University Hospital Assistance Publique - Hôpitaux de Marseille Marseille, France Departments of Addictology and Psychiatry Sainte-Marguerite University Hospital Assistance Publique - Hôpitaux de Marseille and Self-Perceived Health Assessment Research Unit Faculty of Medicine Aix Marseille University Marseille, France Department of Addictology Sainte-Marguerite University Hospital Assistance Publique - Hôpitaux de Marseille and Department of Clinical Pharmacology Timone University Hospital Assistance Publique - Hôpitaux de Marseille and Self-Perceived Health Assessment Research Unit Faculty of Medicine Aix Marseille University Marseille, France.
No abstract available in PubMed .
Related Concept Videos
Cardiac Action Potential
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiopulmonary Resuscitation IV: Pharmacological Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

